32nd week of 2022 patent applcation highlights part 25 |
Patent application number | Title | Published |
20220250995 | High Emissivity Cerium Oxide Coating - The present invention relates to a coating composition comprising: 10 to 80 wt % of cerium oxide comprising a dopant based upon the total weight of the composition, wherein said dopant is selected from iron oxide, cobalt oxide, chromium oxide, lanthanum oxide, or mixtures thereof, and the atomic ratio of dopant metal to cerium is in the range 0.01:1 to 0.5:1; and 10 to 50 wt % of binder based upon the total weight of the composition. | 2022-08-11 |
20220250996 | HIGH TEMPERATURE COATINGS - A method includes forming a crystallized metal carbide undercoat on a surface of a carbon-carbon composite substrate. The method further includes forming an overcoat on a surface of the undercoat. The overcoat includes a plurality of crystallized ultra-high melting point overcoat layers. Each overcoat layer is sequentially formed by applying a mixture to a surface of an underlying layer and heating the mixture. The mixture includes a plurality of ultra-high melting point refractory ceramic particles and a pre-ceramic polymer. The mixture is heated to a heat treatment temperature to pyrolyze the pre-ceramic polymer and form the overcoat layer in an inert atmosphere or under vacuum. As a result, the overcoat layer includes a crystallized ultra-high melting point polymer-derived ceramic matrix that includes the plurality of ultra-high melting point refractory ceramic particles. | 2022-08-11 |
20220250997 | HIGHLY EFFICIENT AND ENVIRONMENT-FRIENDLY REACTIVE EXTRUSION INTEGRATED CONTINUOUS PREPARATION PROCESS FOR A BIODEGRADABLE POLYMERIC MULTI-NUTRIENT NANO SLOW/CONTROLLED-RELEASE FERTILIZER - The present invention discloses a highly efficient and environment-friendly reactive extrusion integrated continuous preparation process for a biodegradable polymeric multi-nutrient elements nano slow/controlled-release fertilizer and a biodegradable polymeric multi-nutrient elements nano slow/controlled-release fertilizer prepared by the process consisting of urea-formaldehyde macromolecular chains and nano-phosphate. Firstly preparing a methylolurea solution, and then feeding the same into a reactive extrusion integrated machine, adding a phosphate, starting the reaction unit of the reactive extrusion integrated machine to carry out the reaction, and simultaneously starting the vacuumizing devolatilization apparatus to remove moisture from the reaction system; after completing the reaction, starting the extrusion unit of the reactive extrusion integrated machine, extruding to obtain a strip-shaped product, and drying and granulating the same to obtain a finished product. The present invention can achieve forced discharge of the output end of the reaction unit by integrating the extrusion unit and the reaction unit, thereby realizing continuous production of the biodegradable polymeric multi-nutrient nano slow/controlled-release fertilizer. The biodegradable polymeric multi-nutrient nano slow/controlled-release fertilizer prepared by the present invention is firmly bonded between macromolecular chains of urea-formaldehyde through hydrogen bonding, which could impart excellent slow-release performances to nitrogen, phosphorus, potassium and other medium and trace elements; thereby the nutrient use efficiency of the fertilizer is greatly improved. | 2022-08-11 |
20220250998 | METHOD FOR ENHANCING HYDROPONIC PLANT PRODUCTIVITY USING GLYCINE BETAINE - The present disclosure provides a new method for enhancing plant productivity and/for reducing leaf necrosis of plant grown hydroponically by using glycine betaine. | 2022-08-11 |
20220250999 | METHOD FOR PRODUCING A FIBROUS MATERIAL FOR FUNGI, WITH USE IN AGRICULTURE, ECOLOGICAL RESTORATION AND INDUSTRIAL APPLICATIONS - A method that allows storage, transport and delivery of fungal propagules in a polymer matrix corresponding to microfibers or nanofibers that carry totally or partially encapsulated propagules infectious between fibrous sheets or adhered on their surface with applications in different inoculation strategies in the field of agriculture, horticulture, forestry, ecological remediation, and related areas. | 2022-08-11 |
20220251001 | METHOD FOR PRODUCING VERMICOMPOST - An object is to realize composting using earthworms of excrement stored under a nonflushing environment such as a temporary toilet. The present invention provides a method for producing vermicompost, including a step of treating excrement with an excrement treatment agent to provide treated excrement, and a step of subjecting the treated excrement to composting in soil containing earthworms. | 2022-08-11 |
20220251002 | ENHANCED EFFICIENCY FERTILIZER WITH UREASE INHIBITOR AND NITRIFICATION INHIBITOR IN SEPARATE PARTICLES - Particulate fertilizer compositions that include nitrification inhibitors and urease inhibitors are described herein. The inhibitors are separated from each other by being in separate particles. Fertilizer particles in the composition include particles having a core-shell structure, with an inhibitor included in the core particle. | 2022-08-11 |
20220251003 | Processes and Systems for C3+ Monoolefin Conversion - Processes and systems for C | 2022-08-11 |
20220251004 | OXIDATIVE DEHYDROGENATION COPRODUCTION - A system and method for coproduction in the production of ethylene, including contacting ethane with an oxidative dehydrogenation (ODH) catalyst in presence of oxygen in a first reactor to dehydrogenate ethane to ethylene, and contacting a first-reactor effluent with an ODH catalyst in a second reactor to form ethanol and acetaldehyde. | 2022-08-11 |
20220251005 | METHODS FOR OPERATING ACETYLENE HYDROGENATION UNITS DURING INTEGRATION OF CHEMICAL PROCESSING SYSTEMS FOR PRODUCING OLEFINS - A method for operating an acetylene hydrogenation unit of a steam cracking system that integrates a fluidized catalytic dehydrogenation (FCDh) effluent from a fluidized catalytic dehydrogenation (FCDh) system may include separating a cracked gas from the steam cracking system into at least a hydrogenation feed comprising at least acetylene, CO, and hydrogen, introducing the FCDh effluent to the separation system, combining the FCDh effluent with the cracked gas upstream of the separation system, or both. The method may include hydrogenating acetylene in the hydrogenation feed. Elevated CO concentration in the hydrogenation feed due to the FCDh effluent may reduce a reaction rate of acetylene hydrogenation. The acetylene hydrogenation unit may operate at an elevated temperature relative to normal operating temperatures when the portion of the FCDh effluent is not integrated, such that a concentration of acetylene in the hydrogenated effluent is less than a threshold acetylene concentration. | 2022-08-11 |
20220251006 | METHODS FOR OPERATING INTEGRATED CHEMICAL PROCESSING SYSTEMS FOR PRODUCING OLEFINS - A method for operating an integrated system for producing olefins may include contacting a hydrogenation feed with a first hydrogenation catalyst to produce a hydrogenated effluent, the hydrogenation feed including at least a portion of a first process effluent from a first olefin production process and at least a portion of a second process effluent from a second olefin production process. The hydrogenation feed may include at least hydrogen, ethylene, carbon monoxide, acetylene, methyl acetylene, and propadiene, and the first hydrogenation catalyst may be a hydrogenation catalyst having a temperature operating range of at least 40° C. The hydrogenated effluent may include methyl acetylene, propadiene, or both. The method may further include contacting at least a portion of the hydrogenated effluent with a second hydrogenation catalyst, which may cause hydrogenation of at least a portion of the methyl acetylene and propadiene to produce an MAPD hydrogenated effluent. | 2022-08-11 |
20220251007 | Industrial Process for Manufacturing of Perfluoropentane (PFP) - The invention relates to a new industrial process for manufacturing of perfluoropen-tane (PFP), and to the manufacture of a novel intermediate compound thereof, as well as to the novel intermediate compound itself and the use thereof in the process for manu-facturing of perfluoropentane (PFP). Accordingly, the invention relates to a process for the manufacture of the compound PFP (perfluoropentane), and/or of the compound perfluorinated 4-methylbutyrolactone, i.e., the precursor or intermediate compound of PFP (perfluoropentane), characterized in that the process comprises direct fluorination reaction with F2 gas as the fluorination agent, and/or from the fluorination reaction with SF4 as the fluorination agent. The present invention provides an efficient and simplified new industrial process for manufacturing of perfluoropentane (PFP) and/or of the compound perfluorinated 4-methylbutyrolactone, and preferably enabling large-scale and/or industrial production of perfluoropentane (PFP) and/or of the compound perfluorinated 4-methylbutyrolactone by means of special equipment and special reactor design. | 2022-08-11 |
20220251008 | METHOD FOR PRODUCING 1,2-DICHLORO-3,3-DIFLUORO-1-PROPENE AND SOLVENT COMPOSITION - By fluorinating 1,2,3,3-tetrachloro-1-propene (1230xd) using hydrogen fluoride as a fluorinating agent, an efficient method for producing 1,2-dichloro-3,3-difluoro-1-propene (1232xd) is provided. Through this composition including 1232xd, there are also provided an environmentally friendly composition having excellent ability to dissolve various organic matters, a method for cleaning an article using the composition, a method for producing a lubricant solution using the composition, and a method for producing a component provided with a lubricant coating film. | 2022-08-11 |
20220251009 | METHOD FOR PRODUCING ALCOHOL - A method for producing an alcohol by hydrating an olefin using a heteropolyacid catalyst is provided, in which the catalyst can be stably used over a long period. The method is for producing an alcohol by supplying water and an olefin having 2-5 carbon atoms to a reactor and hydrating the olefin in a gas phase using a solid acid catalyst loaded with a heteropolyacid or a salt thereof, and is characterized in that a raw-material mixture to be supplied to the reactor has an aldehyde compound content of 70 mol ppm or less. | 2022-08-11 |
20220251010 | METHOD AND SYSTEM FOR THE SYNTHESIS OF METHANOL - A method for synthesizing methanol, wherein a fuel stream containing carbon is supplied to a synthesis gas reactor arrangement to obtain a synthesis gas stream including hydrogen and carbon oxides that is supplied to a first reactor stage of a methanol reactor arrangement for partial conversion into methanol, and is obtained with a generation pressure higher than the synthesis pressure with which the synthesis gas stream is partially converted into methanol. A residue gas stream is obtained from the methanol reactor arrangement, supplied to a recycle compressor and to the methanol reactor arrangement. Before being supplied to the first reactor stage, the synthesis gas stream is supplied to a heat recovery device to recover heat. A recovery stream is supplied to a hydrogen recovery arrangement to obtain an H-recycle stream. The pressure of the unreacted hydrogen is increased before it is supplied again to the first reactor stage. | 2022-08-11 |
20220251011 | 1,3-BUTANEDIOL - The purpose of the present invention is to stably provide 1,3-butanediol which is less odorous and is suitable for use in cosmetics. The 1,3-butanediol has a. content of odorous substance A, which is represented by chemical formula (A), of 2-10 wtppm and a content of odorous substance B, which is represented by chemical formula (B), of 4-25 wtppm. | 2022-08-11 |
20220251012 | METHOD OF DECOMPOSING PHENOLIC BY-PRODUCT - The present disclosure relates to a method of decomposing a phenolic by-product, including: a step of feeding and thermally cracking a phenolic by-product stream to and in a decomposition apparatus, recovering an active ingredient from a top discharge stream, and discharging a high-boiling substance through a bottom discharge stream; a step of pressurizing each of a side discharge stream of the decomposition apparatus and a bottom discharge stream of the decomposition apparatus; a step of mixing the pressurized side discharge stream of the decomposition apparatus and the pressurized bottom discharge stream of the decomposition apparatus with each other to form a mixed stream; and a step of passing a part of the mixed stream through a reboiler, circulating the part of the mixed stream to the decomposition apparatus, and discharging a residual mixed stream. | 2022-08-11 |
20220251013 | METHOD FOR PRODUCING SECONDARY ALCOHOL ALKOXYLATE - The present invention is to provide a means that can reduce coloring of secondary alcohol alkoxylate. The present invention relates to a method for producing a secondary alcohol alkoxylate which comprises feeding an alkylene oxide from a plurality of positions in a tubular reactor to a secondary alcohol to react them, wherein the alkylene oxide is fed in such a manner that a feeding interval is extended and a feeding rate is increased each with a specific proportion. | 2022-08-11 |
20220251014 | 1-ALKOXYETHYL-4-ISOBUTYL-BENZENE AS AROMA INGREDIENTS - The presently claimed invention is directed to the use of 1-alkoxyethyl-4-isobutyl-benzene of formula (I) to impart an aroma impression to a composition. The presently claimed invention also relates to a method of imparting such aroma impression. The present invention is further directed to compositions comprising the compound of formula (I) and at least one aroma chemical as well as to compositions comprising the compound of formula (I) and at least one further component selected from the group consisting of aroma chemicals, surfactants, oil components, anti-oxidants, deodorant-active agents and solvents. The present invention also relates to a compound of formula (I′). | 2022-08-11 |
20220251015 | A METHOD FOR REDUCING HEAVY END FORMATION AND CATALYST LOSS IN A HYDROFORMYLATION PROCESS - The present invention refers to a method for reducing heavy end formation and catalyst loss in a continuous hydroformylation process, where an olefin or an olefin mixture is reacted with carbon monoxide and hydrogen in a reactor assembly ( | 2022-08-11 |
20220251016 | CATALYST SYSTEM FOR OLEFIN POLYMERIZATION AND USE THEREOF - A catalyst system for olefin polymerization contains a main catalyst and a cocatalyst. The cocatalyst contains a twelve-membered ring compound represented by formula (M). The catalyst system is suitable for preparing polypropylene products having high stereoregularity and low ash, and can regulate the melt index of the products within a wide range by adjusting the amount of hydrogenation. It is also suitable for copolymerization systems to improve the copolymerization yield. | 2022-08-11 |
20220251017 | CRYSTAL FORM I OF CURCUMIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - Provided are a crystal form I of a curcumin derivative (C66), a preparation method therefor and an application thereof. An X-ray powder diffraction pattern of the crystal form I contains following characteristic peaks for 2θ reflection angle determination: 8.4±0.2°, 11.5±0.2°, 13.1±0.1°, 16.6±0.2°, 18.8±0.1°, and 21.2±0.1°. No sharp diffraction peak exists at 33.5±0.2° and 38.1±0.2°. A structure of the curcumin derivative is shown in formula (I) as follows: | 2022-08-11 |
20220251018 | PRODUCTION SYSTEM/PRODUCTION PROCESS FOR ACRYLIC ACID AND PRECURSORS THEREOF - Provided herein are systems, and methods of using such systems, for producing acrylic acid from ethylene oxide and carbon monoxide on an industrial scale. The composition includes: polypropiolactone having a concentration of greater than at least 90 wt %; a residual cobalt or ions thereof from a carbonylation catalyst in an amount of 10 ppm or less; acetic acid in an amount of 10 ppm or less; and tetrahydrofuran in amount of 10 ppm or less. | 2022-08-11 |
20220251019 | METHOD FOR PRODUCING GLYCEROL MONO(METH)ACRYLATE - The invention relates to a method for producing glycerol mono(meth)acrylate from 2,2-dimethyl-1,3-dioxolan-4-ylmethyl (meth)acrylate by acid-catalysed reaction with methanol. | 2022-08-11 |
20220251020 | ESTER SYNTHESIS USING HETEROGENEOUS AU/TIO2 CATALYST - A process for direct esterification of an alkyl aldehyde with an alkyl alcohol to produce an alkyl ester is disclosed. The process comprises reacting an alkyl aldehyde with an alkyl alcohol in the presence of an Au/TiOa catalyst, a base and an enal or oxygen to form an ester and an aldehyde. The process avoids liberation of water and avoids the step of oxidation of the alkyl aldehyde to an alkyl acid. | 2022-08-11 |
20220251021 | AKR1C3 INHIBITOR AND MEDICAL USE - Described are compounds that act as AKR1C3 inhibitors or pharmaceutically acceptable salts or solvates or isotopically substituted compounds thereof and methods thereof. | 2022-08-11 |
20220251022 | METHOD FOR PRODUCING AROMATIC AMINOMETHYL - A method for producing an aromatic aminomethyl, comprising hydrogenating an aromatic nitrile in a mixed solvent comprising a hydrocarbon solvent and a polar organic solvent having a solubility parameter (SP value) of 10 or more in the presence of a quaternary ammonium compound and a hydrogenation catalyst. | 2022-08-11 |
20220251023 | METHOD FOR PREPARING AMANTADINE - A method for preparing amantadine includes chlorinating adamantane with chlorine gas in a solvent in the presence of a Lewis acid catalyst to obtain a reaction liquid, and then removing the solvent and residues containing the catalyst in the reaction liquid, to obtain a chlorinated product. The chlorinated product is mixed with urea to a mixture, and the mixture is subjected to an amination reaction, to obtain amantadine. The results of examples show that the purity of the prepared amantadine could reach 99.5% or more. | 2022-08-11 |
20220251024 | Dibromobenzyl Derivative, Stereoisomer Or Salt Thereof, And Preparation Method And Application Of Dibromobenzyl Derivative - A dibromobenzyl derivative with a structure shown as formula I, a stereoisomer or a pharmaceutically acceptable salt thereof and a preparation method and an application of the dibromobenzyl derivative are provided. The dibromobenzyl derivative or the stereoisomer thereof is superior in in-vivo pharmacokinetic stability and drug efficacy, and capable of being used for preparing respiratory drugs, in particular the apophlegmatic drugs. | 2022-08-11 |
20220251025 | AUTOMATED ULTRA-COMPACT MICRODROPLET RADIOSYNTHESIZER - A chemical synthesis platform based on a particularly simple chip is described herein, where reactions take place atop a hydrophobic substrate patterned with a circular hydrophilic liquid trap. The overall supporting hardware (heater, rotating carousel of reagent dispensers, etc.) can be packaged into a very compact format (about the size of a coffee cup). We demonstrate the consistent synthesis of [ | 2022-08-11 |
20220251026 | METHOD FOR PRODUCING HIGHLY POLYMERIZABLE N-VINYL CARBOXLYIC ACID AMIDE MONOMER - A method for producing a highly polymerizable N-vinyl carboxylic acid amide monomer includes (A) melting a crude N-vinyl carboxylic acid amide monomer including 50 to 88 mass % of an N-vinyl carboxylic acid amide monomer by heating, followed by cooling for precipitation, and subjecting precipitated N-vinyl carboxylic acid amide monomer crystals to solid-liquid separation (step (A)), and (B) further dissolving the N-vinyl carboxylic acid amide monomer crystals separated in step (A) in a mixed solvent of 1,2-dimethoxyethane and an aliphatic hydrocarbon having 6 to 7 carbon atoms, then performing crystallization, performing solid-liquid separation, and recovering an N-vinyl carboxylic acid amide monomer purified product (step (B)), wherein a mass ratio of 1,2-dimethoxyethane/N-vinyl carboxylic acid amide monomer crystal in step (B) is 0.01 to 0.5, and a mass ratio of aliphatic hydrocarbon having 6 to 7 carbon atoms/N-vinyl carboxylic acid amide monomer crystal in step (B) is 0.5 to 3.0. | 2022-08-11 |
20220251027 | BENZIDINE COMPOUND AND APPLICATION THEREOF - The present application relates to a benzidine compound and an application thereof, the benzidine compound having the structure as shown in formula I below. Further provided in the present application are a pharmaceutically acceptable salt, isomer, racemate, prodrug co-crystal complex, hydrate, and solvate of the compound, as well as an application thereof in the preparation of a drug for the treatment or prevention of RORγ-regulated diseases; more importantly, such a compound can also be used in the preparation of a drug for the treatment of inflammation, immune diseases, cancer and neurological diseases. | 2022-08-11 |
20220251028 | TERTIARY AMINE DERIVATIVES AND THEIR USES FOR TREATING A VIRAL INFECTION - The present invention relates to a new class of tertiary amine derivatives of formula (I) and their uses for treating viral infections, particularly viral respiratory infections. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I). | 2022-08-11 |
20220251029 | COMPOUND, COMPOSITION, FILM, LAMINATE, AND DISPLAY DEVICE - Provided is a compound represented by formula (1). In formula (1), Ar | 2022-08-11 |
20220251030 | ACETONITRILE SEPARATION PROCESS - Provided herein are processes for the separation of acetonitrile from low-purity feedstock streams. The provided processes are particularly useful for isolating acetonitrile at high purity from chemical manufacturing waste streams that include methanol, water, and allyl alcohol. | 2022-08-11 |
20220251031 | Crystalline Form of y-Aminobutyric Acid Analog - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 2022-08-11 |
20220251032 | FERRITIC STEEL PARTS IN UREA PLANTS - The application provides in an aspect a process for producing urea in a urea plant comprising a high pressure synthesis section comprising a reactor, wherein the process comprises reacting NH | 2022-08-11 |
20220251033 | A PROCESS FOR THE SYNTHESIS OF UREA - A process for synthesis of urea from ammonia and carbon dioxide comprising the synthesis of urea in parallel in a first urea reactor ( | 2022-08-11 |
20220251034 | Preparation Method for Metformin Hydrochloride - The present disclosure provides a preparation method for metformin hydrochloride. The preparation method includes: microwave heating raw materials containing dicyandiamide and dimethylamine hydrochloride, and reacting the two at 100° C. to 160° C. to obtain a product system containing metformin hydrochloride. Microwave heating is adopted to heat the dicyandiamide and the dimethylamine hydrochloride. Compared with a conventional heating mode that requires heat to be gradually transferred from the outside to the inside, microwave heating can directly heat each part inside the reactant, which can make the internal temperature of the reactant more uniform, thereby reducing the generation of impurities. | 2022-08-11 |
20220251035 | NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION - Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate Nrf2 to relieve inflammatory damage and improve an inflammatory microenvironment, has a potential anti-inflammatory activity, and can be used for preparing an anti-inflammatory drug for inflammatory damage of various inflammation-related diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, intestinal Inflammations, rheumatoid arthritis, etc. | 2022-08-11 |
20220251036 | DIFLUOROHALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES, METHODS OF PREPARATION, AND USES THEREOF - The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer and/or scarring in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as uses thereof. | 2022-08-11 |
20220251037 | SOLID PEROXYALPHAHYDROXYCARBOXYLIC ACID GENERATION COMPOSITIONS AND THE USE THEREOF - Peroxyhydroxycarboxylic acid forming compositions and methods for forming peroxyhydroxycarboxylic acids, preferably in situ, using the peroxyhydroxycarboxylic acid forming compositions are disclosed. Methods of using the peroxyhydroxycarboxylic acids, including for treating a surface or a target in need of antimicrobial or sanitizing treatment are also disclosed. Particular applications of using odor-free, low volatility peroxyhydroxycarboxylic acid sanitizers for direct food contact are disclosed. | 2022-08-11 |
20220251038 | PROCESS FOR THE PRODUCTION OF DIACYL PEROXIDES - Process for the production of a diacyl peroxide involving the reaction of an anhydride with hydrogen peroxide, removal of the formed carboxylic acid, production of an anhydride from said carboxylic acid, and recycling of the anhydride within the process. | 2022-08-11 |
20220251039 | Diaryl-B-Lactam Compound and Preparation Method and Pharmaceutical Use Thereof - The present invention relates to the field of synthetic medicinal chemistry and provides a series of novel diaryl-β-lactam compounds having significant anti-tumor activity, and the pharmaceutical use thereof. The present invention also comprises the use of these compounds, pharmaceutical salts, and pharmaceutical composition thereof for preparing a pharmaceutical for the prevention or treatment of tumor-associated disease. The diaryl-β-lactam compounds of the present invention have the following general formula (I). | 2022-08-11 |
20220251040 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS - The present invention provides N-substituted indoles and other heterocycles and methods of using the compounds for treating brain disorders. | 2022-08-11 |
20220251041 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS - The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R | 2022-08-11 |
20220251042 | TOTAL SYNTHESIS OF PIRFENIDONE - The present invention relates to a process for the synthesis of Pirfenidone (1) from 5-Methyl-3,4-dihydro-2-pyridone and halobenzene (chlorobenzene, bromobenzene, or iodobenzene) in the presence of a catalytic system consisting of a copper salt and an organic ligand, in the presence of a base. | 2022-08-11 |
20220251043 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN - Disclosed herein are hydroxamic acid compounds. Also disclosed is a method of using the hydroxamic acid compounds for treating a condition associated with histone deacetylase 6. | 2022-08-11 |
20220251044 | CRYSTAL FORM OF HYPOXIA-INDUCIBLE FACTOR-PROLYL HYDROXYLASE INHIBITOR - A novel crystalline form of Compound I and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing hypoxia inducible factor prolyl hydroxylase inhibitor drugs and drugs for treating conditions mediated by hypoxia inducible factors. Compared with prior arts, the crystalline form of Compound I have one or more improved properties, which is of great value to the optimization and development of the drugs. | 2022-08-11 |
20220251045 | MCT4 INHIBITORS FOR TREATING DISEASE - Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I | 2022-08-11 |
20220251046 | SUBSTITUTED PYRAZOLE COMPOUNDS, COMPOSITIONS CONTAINING SAME, AND USE THEREOF - The present invention provides substituted pyrazole compounds, compositions containing same, and use thereof. The substituted pyrazole compounds comprise a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate, or solvate thereof. The compound represented by formula (I) can serve as a tissue selective androgen receptor modulator (SARM), particularly serving as a drug for treating prostate cancer and other AR-dependent conditions and diseases in which AR antagonism is desired. | 2022-08-11 |
20220251047 | HETEROCYCLIC INHIBITORS OF MCT4 - Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: | 2022-08-11 |
20220251048 | TEAD INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2022-08-11 |
20220251049 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described. | 2022-08-11 |
20220251050 | IMPACT OF TRACE ELEMENTS IN THE GRIGNARD REACTION - The present invention relates to an improved process for preparing 2,4-dichloro-6-(4-methoxyphenyl)-1,3,5-triazine (DICAT) comprising reacting 4-bromoanisole with magnesium, and reacting the resulting Grignard reagent with cyanuric chloride, wherein the magnesium comprises additional metals as impurities in an amount of less than 0.027% by weight, based on the total weight of the magnesium. | 2022-08-11 |
20220251051 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE THEREOF - The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic electroluminescent device having an operating voltage lower than that of a conventional organic electroluminescent device and thus achieving higher power efficiency. | 2022-08-11 |
20220251052 | IMPROVED PROCESS FOR THE PREPARATION OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF - The present invention relates to process for the preparation of 2-(3,5-dichlorophenyl)-1,3- benzoxazole-6-carboxylic acid of formula (I), its pharmaceutically acceptable salts and polymorphs thereof which are used in the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis. | 2022-08-11 |
20220251053 | PROCESS OF PREPARING 2-(PHENYLIMINO)-1,3-THIAZOLIDIN-4-ONES - The present invention relates to a method for preparing 2-(phenylimino)-1,3-thiazolidin-4-ones of the general formula (I). | 2022-08-11 |
20220251054 | Analogues and Methods of Treating Rett Syndrome - Disclosed herein are Pifithrin compounds, methods of treating Rett Syndrome, brain fusion organoids comprising a fusion between a cerebral cortex (Cx) organoid and the ganglionic eminence (GE) organoid, one of which comprises, consists essentially of, or consists of neural cells having a loss of function mutation in the Methyl-CpG Binding Protein 2 (MECP2) gene, and methods of using the brain fusion organoid to screen for candidate compounds that treat, reduce, or inhibit the abnormal neural activities caused by MECP2-mutations. | 2022-08-11 |
20220251055 | PROCESS FOR THE SYNTHESIS OF VORTIOXETINE - The present invention relates to a process for the synthesis of Vortioxetine (I) or a pharmaceutically acceptable salt thereof. This process is accomplished by using a catalytic system consisting of a copper salt and an organic ligand, which can promote the formation of both C—N and C—S bond in one-pot, giving rise to an efficient, simple and industrially viable synthetic route for Vortioxetine. | 2022-08-11 |
20220251056 | DIOL COMPOUND, POLYCARBONATE, AND PREPARATION METHOD THEREOF - Provided are a diol compound which may be used to prepare a polycarbonate having excellent weather resistance, hardness, heat resistance, transparency, impact resistance, etc. while having excellent mechanical properties, a polycarbonate prepared by using the same, and a preparation method thereof. | 2022-08-11 |
20220251057 | IMPROVED METHODS FOR CONVERTING CANNABIDIOL INTO DELTA9-TETRAHYDROCANNABINOL UNDER PROTIC REACTION CONDITIONS - Disclosed herein is a method for converting cannabidiol (CBD) into a composition comprising Δ | 2022-08-11 |
20220251058 | METHODS FOR PREPARING CANNABINOIDS BY HETEROGENEOUS-ACID-PROMOTED DOUBLE-BOND MIGRATION - Disclosed is a method for converting a first cannabinoid into a second cannabinoid that is a regioisomer of the first cannabinoid. The method comprises contacting the first cannabinoid with a Lewis-acidic heterogeneous reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range for the Lewis-acidic heterogeneous reagent and the first cannabinoid; and (ii) a reaction time that is within a target reaction-time range for the Lewis-acidic heterogeneous reagent, the reaction temperature, and the first cannabinoid. | 2022-08-11 |
20220251059 | METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUND - Provided is a novel production method capable of easily producing a methylene disulfonate compound. The method for producing a methylene disulfonate compound comprises reacting a specific sulfonic acid compound with a formaldehyde compound in the presence of sulfur trioxide. | 2022-08-11 |
20220251060 | METHOD FOR PRODUCING CYCLIC DISULFONIC ACID ESTER COMPOUND - Provided is a novel production method capable of easily producing a cyclic disulfonic acid ester compound. This method for producing a cyclic disulfonic acid ester compound comprises reacting a specific sulfonic acid compound with a specific sulfuric acid ester compound. | 2022-08-11 |
20220251061 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION - Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein. | 2022-08-11 |
20220251062 | INHIBITORS OF BACTERIAL PASTA KINASES - Biochemically active PASTA kinase inhibitors which exploit subtle structural differences between human kinases and bacterial PASTA kinases to improve specificity and inhibitor activity. The disclosed kinase inhibitors have the general formula: | 2022-08-11 |
20220251063 | COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE THEREOF - Provided are a compound for an organic electric device, an organic electric device using the same, and an electronic device including the organic electric device. According to the presently claimed subject matter, an organic electric device with high luminous efficiency, low driving voltage, and high heat resistance can be provided, and the color purity and lifetime of the organic electric device can be improved. | 2022-08-11 |
20220251064 | A Substituted Tetrahydroisoquinoline Derivative as a D1 Positive Allosteric Modulator - The present invention relates to compounds according to formula (I), which are a positive allosteric modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role. | 2022-08-11 |
20220251065 | IRE1 SMALL MOLECULE INHIBITORS - Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer. | 2022-08-11 |
20220251066 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH - The present invention relates to a compound of the formula I | 2022-08-11 |
20220251067 | NLRP3 INFLAMMASOME INHIBITORS - The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): | 2022-08-11 |
20220251068 | PYRIDIN-3-YL DERIVATIVES - The present invention relates to pyridin-3-yl derivatives of Formula (I) | 2022-08-11 |
20220251069 | SOLID FORMS OF AN HIV CAPSID INHIBITOR - The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yOpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus. | 2022-08-11 |
20220251070 | METHODS OF MAKING TRANS ISOMERIC FORMS OF G PROTEIN-COUPLED RECEPTOR MODULATORS - Disclosed herein, inter alia, methods of synthesis of trans isomeric forms of G protein-coupled receptor modulators of high trans isomeric purity. | 2022-08-11 |
20220251071 | METHOD TO MAKE SMALL-MOLECULE MURINE DOUBLE MINUTE 2 PROTEIN (MDM2)-DEGRADING COMPOUNDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of the formula: | 2022-08-11 |
20220251072 | Process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide - A process can be used for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide. | 2022-08-11 |
20220251073 | CRYSTALLINE FORMS OF 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METH- YL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOL- E-5-CARBOXAMIDE - The present disclosure relates to a crystalline Form 1 of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-di -methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d] [1,3]dioxole-5-carboxamide, which is useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders. | 2022-08-11 |
20220251074 | HERBICIDAL AMIDES - The present invention relates to amides of formula (I), wherein the variables are defined according to the description, process for preparation, their use as herbicides, i.e. for controlling harmful plants, and also a method for controlling unwanted vegetation which comprises allowing a herbicidal effective amount of at least one amide of formula (I) to act on plants, their seed and/or their habitat. | 2022-08-11 |
20220251075 | Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, Y, R | 2022-08-11 |
20220251076 | Inhibitors of Beta-Hydoxylase for Treatment of Cancer - The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders. | 2022-08-11 |
20220251077 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME - An organic compound is described. An organic electroluminescence device comprises the organic compound as a host or an electron transfer layer. The organic compound of the following formula may lower a driving voltage or increase a current efficiency or a half-life of the organic electroluminescence device. | 2022-08-11 |
20220251078 | Continuous Process for the Preparation of Anticholinergic Drugs - The present invention relates to a novel process for the preparation of anticholinergic agents/drugs, such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide, ipratropium bromide (V) in continuous flow mode in the presence of one or more polar protic solvents. The anticholinergic drugs are in a form suitable for use in inhalation in the treatment of respiratory diseases such as asthma or chronic obstructive pulmonary disease (COPD). | 2022-08-11 |
20220251079 | BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE - Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided. | 2022-08-11 |
20220251080 | SUBSTANTIALLY PURE VENETOCLAX AND AMORPHOUS VENETOCLAX IN A FREE DRUG PARTICULAT E FORM - The present invention provides substantially pure venetoclax, process for the preparation of substantially pure venetoclax and pharmaceutical formulation of substantially pure venetoclax. In another aspect present invention provides amorphous venetoclax in a free drug particulate form, process for the preparation of amorphous venetoclax in a free drug particulate form and pharmaceutical formulation of amorphous venetoclax in a free drug particulate form. | 2022-08-11 |
20220251081 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER - The present disclosure provides for compounds according to Formula I, Formula II, and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as described in the disclosure. The compounds are inhibitors of methionine adenosyltransferase isoform 2A (MAT2A). Also provided are pharmaceutical compositions and methods of using the compounds for treating cancers, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted. | 2022-08-11 |
20220251082 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) - The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds. | 2022-08-11 |
20220251083 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS - Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 2022-08-11 |
20220251084 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME - Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD). | 2022-08-11 |
20220251085 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF - Purine-derived covalent probes (e.g., halo or di-halo-substituted purine based covalent probes) and related ligands are described. The compounds can be used to identify reactive nucleophilic amino acid residues, such as reactive cysteine residues, in proteins and to modify the activity of proteins with reactive nucleophilic amino acid residues (e.g., reactive cysteine residues) via the formation of protein adducts comprising the ligands Modified proteins prepared from the probes and ligands are also described. | 2022-08-11 |
20220251086 | COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE COMPOUND - Specific compounds represented by formula (1), a material for an organic electroluminescence device comprising said specific compound, an organic electroluminescence device comprising said specific compound, an electronic equipment comprising said organic electroluminescence device and the use of said compounds in an organic electroluminescence device. | 2022-08-11 |
20220251087 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS - This application relates to compounds of Formula (I): | 2022-08-11 |
20220251088 | Processes for Making PRMT5 Inhibitors - The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided. | 2022-08-11 |
20220251089 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS - Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to B-Raf V600E kinase. | 2022-08-11 |
20220251090 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM - This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body. | 2022-08-11 |
20220251091 | AMORPHOUS UMBRALISIB MONOTOSYLATE - The present disclosure is directed to amorphous umbralisib monotosylate, and to processes for its preparation; pharmaceutical compositions comprising amorphous umbralisib monotosylate; and to a method for treating a patient using amorphous umbralisib monotosylate. | 2022-08-11 |
20220251092 | CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF - Disclosed is a novel substituted pyrazolopyrimidine compound that inhibits the activity of casein kinase 1ε (CK1ε) and a stereoisomer or stereoisomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, and an application thereof in preparation of drugs for treating diseases, disorders or conditions that benefit from the inhibition of the activity of the casein kinase 1ε (CK1ε). The compound of the present invention has an inhibitory activity on CK1ε kinase, OCI-LY10 cells and Karpas299 cells, shows good anti-tumor activity in an OCI-LY10 subcutaneous xenogeneic model and shows excellent synergistic anti-tumor activity in combination with BTK inhibitors. The compound of the present invention has good pharmacokinetics properties and may be used alone or in combination with other drugs to treat diseases, disorders or conditions that benefit from the inhibition of the activity of the casein kinase 1ε, the diseases, disorders or conditions comprising tumors, autoimmune diseases, etc. | 2022-08-11 |
20220251093 | POTASSIUM SALT CRYSTAL FORM B OF PHOSPHODIESTERASE TYPE 5 INHIBITOR, AND PREPARATION METHOD AND USE THEREFOR - Disclosed in the present disclosure are a potassium salt crystal form B of a phosphodiesterase type 5 inhibitor, and a preparation method and a use therefor. The structural formula of the phosphodiesterase type 5 inhibitor is as shown in a formula (I), and the X-ray powder diffraction (XRPD) pattern of the potassium salt crystal form B has characteristic peaks at the following 2θ angles: 5.71°±0.2°, 8.23°±0.2°, 11.37°±0.2°, 13.22°±0.2°, 17.09°±0.2°, 21.56°±0.2°, 23.99°±0.2°, and 25.85°±0.2°. Further disclosed in the present disclosure is a use for the present crystal form potassium salt in preparing drugs for treating pulmonary hypertension, idiopathic pulmonary fibrosis, renal fibrosis, myocardial hypertrophy, or erectile dysfunction. | 2022-08-11 |
20220251094 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS - The present invention discloses a fused heterocyclic compound of formula (I), | 2022-08-11 |
20220251095 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF - A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor. | 2022-08-11 |